This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
← Back to trials NCT07076498
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-04-23Est. Completion: 2029-12-31
Enrollment target: 20 participantsLocations The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States Other microbiome trials you might be interested in Low Grade Astrocytoma Low Grade Glioma Metastatic Low Grade Astrocytoma Metastatic Low Grade Glioma WHO Grade 1 Glioma WHO Grade 2 Glioma
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincr…
Birmingham, United States Est. completion Dec 31, 2030
Ependymoma High Grade Gliomas
Pediatric patients 6-21 years of age with supratentorial recurrent, refractory, or progressive pediatric ependymoma and …
Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation | MicrobiomeTrials Chicago, United States Est. completion Mar 2028
Malignant Glioma
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radi…
Birmingham, United States Est. completion Jun 30, 2027